Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate

Life Sciences

Volumn 73, Issue 3, 2003, Pages 253-263

  Chung, Won Suk ^a   Kim, Eun Jung ^a   Lee, Inchul ^b   Kim, Sang Geon ^a   Lee, Myung Gull ^a   Kim, So Hee ^c  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Gangneung Wonju National University   (South Korea)

Author keywords

6 Hydroxychlorzoxazone; Chlorzoxazone; CYP2E1; Pharmacokinetics; rGH; U ARF

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; DRUG METABOLITE; HUMAN GROWTH HORMONE; UNCLASSIFIED DRUG; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 0037904517     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00268-6     Document Type: Article

References (32)

1. Carriere V., Goasduff T., Ratanasavanh D., Morel F., Gautier J.C., Guillouza A., Beaune P., Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chemical Research in Toxicology. 6(6):1993;8528-8557.
2. Chen L., Yang C.S. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sciences. 58(18):1996;1575-1585.
3. Chiou W.L. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. Journal of Pharmacokinetics and Biopharmaceutics. 6(6):1978;539-549.
4. Chiou W.L. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. Journal of Pharmaceutical Sciences. 68(8):1979;1067-1069.
5. Chiou W.L. New calculation method of mean total body clearance of drugs and its application to dosage regimens. Journal of Pharmaceutical Sciences. 69(1):1980;90-91.
6. Chung H.C., Kim S.H., Lee M.G., Kim S.G. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by acute renal failure. Drug Metabolism and Disposition. 30(6):2002;739-746.
7. Conney A.H., Burns J.J. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. Journal of Pharmacology and Experimental Therapeutics. 128:1960;340-343.
8. Danhof M., Hisaoka M., Levy G. Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentration in rats at onset of loss of righting reflex. Journal of Pharmacology and Experimental Therapeutics. 230(3):1984;627-631.
9. Desiraju R.K., Renzi N.L. Jr., Nayak R.K., Ng K.T. Pharmacokinetics of chlorzoxazone in humans. Journal of Pharmaceutical Sciences. 72(9):1983;991-994.
10. Eatman F.B., Colburn W.A., Boxenbaum H.G., Posmanter H.N., Weinfeld R.E., Ronfeld R., Weissman L., Moore J.D., Gibaldi M., Kaplan S.A. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. Journal of Pharmacokinetics and Biopharmaceutics. 5(5):1977;481-494.
11. Engineer M.S., Ho D.W., Bodey G.P. Sr. Comparison of vancomycin disposition in rats with normal and abnormal renal functions. Antimicrobial Agents and Chemotherapy. 20(6):1981;718-722.
12. Fruncillo R.J., Swanson B.N., Bernhard R., Marchion C., Ferguson R.K. Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. Journal of Pharmaceutical Sciences. 75(2):1986;150-154.
13. Frye R.F., Stiff D.D. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography Biomedical Application. 686(2):1996;291-296.
14. Gibaldi M., Perrier D. Pharmacokinetics. 2nd ed. 1982;Marcel-Dekker, New York.
15. Gorski J.C., Jones D.R., Wrighton S.A., Hall S.D. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 27(3):1997;243-256.
16. Jayyosi Z., Knoble D., Muc M., Erick J., Thomas P., Kelley M. Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 273(3):1995;1156-1161.
17. Kim S.H., Choi Y.M., Lee M.G. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. Journal of Pharmacokinetics and Biopharmaceutics. 21(1):1993;1-17.
18. Kim Y.G., Yoon E.J., Yoon W.H., Shim H.J., Lee S.D., Kim W.B., Yang J., Lee M.G. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharmaceutics and Drug Disposition. 17(3):1996;183-195.
19. Kim S.H., Shim H.J., Kim W.B., Lee M.G. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrobial Agents and Chemotherapy. 42(5):1998;1217-1221.
20. Lee Y.-H., Lee M.-H., Shim C.-K. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharmaceutical Research. 9(12):1992;1599-1606.
21. Lewis D.F.V. P450 substrate specificity and metabolism, in Cytochromes P450 Structure, Function and Mechanism. 1996;123 Talyor and Francis, Bristol.
22. Lin J.H., Lin T.H. Renal handling of drugs in renal failure. I: Differential effects of uranyl nitrate- and glycerol-induced acute renal failure on renal excretion of TEAB and PAH in rats. Journal of Pharmacology and Experimental Therapeutics. 246(3):1988;896-901.
23. Liu J.H., Malone R.S., Stallings H., Smith P.C. Influence of renal failure in rats on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins. Journal of Pharmacology and Experimental Therapeutics. 278(1):1996;277-283.
24. Ono S., Hatanaka T., Hotta H., Tsutsui M., Satoh T., Gonzalez F.J. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics. 5(3):1993;143-150.
25. Park J.M., Moon C.-H., Lee M.G. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Research Communications in Molecular Pathology and Pharmacology. 93(3):1996;353-362.
26. Park K.J., Yoon W.H., Kim S.H., Shin W.G., Lee M.G. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharmaceutics and Drug Disposition. 19(3):1998;141-146.
27. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chemical Research in Toxicology. 3(6):1990;566-573.
28. Rockich K., Blouin R. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metabolism and Disposition. 27(9):1999;1074-1077.
29. Shim H.J., Lee E.J., Kim S.H., Kim S.H., You M., Kwon J.W., Kim W.B., Lee M.G. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharmaceutics and Drug Disposition. 21(7):2000;285-291.
30. Shimada T., Tsumura F., Tamazaki H. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metabolism and Disposition. 27(11):1999;1274-1280.
31. Son M.H., Kang K.W., Kim E.J., Ryu J.H., Cho H., Kim S.H., Kim W.B., Kim S.G. Role of glucose utilization in the restoration of hypophysectomy-induced hepatic cytochrome P450 by growth hormone in rats. Chemico-Biological Interaction. 127(1):2000;13-28.
32. Terao N., Shen D.D. Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats. Journal of Pharmacokinetics and Biopharmaceutics. 12(5):1984;479-493.